1-6 of 6
Heribert Ramroth
Close
Sort by
Journal Articles

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Emmanuel Gyan, Maria Chiara Tisi, Francesco Merli, Luca Baldini, Francesco Di Raimondo, Santiago Mercadal, Benedetta Puccini, Elisabeth Vandenberghe, Ka Lung Wu, Anthony Boland, Rikisha Shah Gupta, Anna van Troostenburg, Carolyn Dunnill, Heribert Ramroth, Nishanthan Rajakumaraswamy, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 1350.
https://doi.org/10.1182/blood-2021-146066
Published: 2021
Journal Articles

Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Gilles Salles, MD PhD, Ka Lung Wu, MD PhD, Sofya Kovalchuk, MD, Santiago Mercadal, MD, Annalisa Chiarenza, MD PhD, Ruth Pettengell, MD, Elisabeth Vandenberghe, MD, Paolo Corradini, MD, Susana Carvalho, MD, Christophe De Belder, MSc, Rikisha Shah Gupta, MPH, Anna van Troostenburg, MD, Nishanthan Rajakumaraswamy, MD, Heribert Ramroth, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-137607
Published: 2020
Journal Articles

A Multicentre, Retrospective Observational Study to Evaluate the Clinical Outcomes of Patients with Chronic Lymphocytic Leukaemia (CLL) Treated with Idelalisib and Rituximab in the UK (RETRO-idel) - a Cohort of 110 Patients

Toby A. Eyre, Gavin Preston, MD, Huseini Hatimbhai Kagdi, MD PhD MBBS, FRCPath, MRCP, Amin Islam, MD, Toby Nicholson, FRCPath, MBBS, MRCP, BA, Christopher Fegan, MB, MD FRCP, FRCPath, Harry W Smith, BSc, MSc, Adam P Cursley, MSc, Heribert Ramroth, PhD, Nishan Rajakumaraswamy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1762.
https://doi.org/10.1182/blood-2019-126845
Published: 2019
Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Christelle M Ferra, Manuel Perez Encinas, MD, Javier Lopez Jimenez, MD, Macarena Ortiz, MD, Santiago Osorio-Prendes, MD, Raul Cordoba, MD PhD, Angel Ramirez Payer, Eva González-Barca, MD PhD, Guillermo Martín Sánchez, MD, Marcos Gonzalez Diaz, MD, Maria Jose Sanchez, MD, Margarita Fernandez, MD, Patricia Baltasar Tello, MD, Elena Amutio, MD, María-Dolores García-Malo, MD, Maria Jesus Vidal Maceñido, MD, Pascual Fernandez, MD, Javier Loscertales, MD, Juan Nicolás Rodríguez, MD, Concha Alaez, MD, Heribert Ramroth, PhD, Margarida Palla
Journal: Blood
Blood (2019) 134 (Supplement_1): 5473.
https://doi.org/10.1182/blood-2019-126588
Published: 2019
Journal Articles

Results from a Prospective Real World Study Show Strong Efficacy of Idelalisib in CLL, Including High-Risk CLL, and Provide Evidence That Pjp Prophylaxis Positively Impacts on Overall Survival

Manuela Hoechstetter, MD, Philipp Eissmann, Nike Hucke, Anna van Troostenburg, Heribert Ramroth, Wolfgang Knauf
Journal: Blood
Blood (2018) 132 (Supplement 1): 4428.
https://doi.org/10.1182/blood-2018-99-112843
Published: 2018
Journal Articles

Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program

Loic Ysebaert, MD PhD, Pierre Feugier, Gilles Andre Salles, MD PhD, Eric Durot, MD, Alexis Talbot, MD, Choquet Sylvain, MD, Denise Glorian Kergaravat, Alastair Simpson, Heribert Ramroth, Tarek Abdelhadi, Corinne Haioun, MD, Xavier Troussard, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5924.
https://doi.org/10.1182/blood-2018-99-110766
Published: 2018